Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, smokeless tobacco products specialist Star Scientific (NAS: STSI) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Star Scientific's business and see what CAPS investors are saying about the stock right now.
Glen Allen, Va. (2000)
Chairman/COO Paul Perito
Return on Capital (average, past 3 years)
Cash / Debt
$10.6 million / $3.8 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 47% of the 322 members who have rated Star Scientific believe the stock will underperform the S&P 500 going forward.
In case you couldn't figure out a way to use Anatabloc to make your life better, now there's Anatabloc face cream "to improve the appearance of the skin". Who doesn't need that? I'm going to wait for the entire line of Anatabloc toiletries to come out -- shaving cream, toothpaste, and deodarant -- and then buy in bulk. Meanwhile, [subsidiary Rock Creek Pharmaceuticals] has initiated a placebo-controlled trial of Anatabloc in Alzheimer's. I heard the delay in starting the trial was because no one was sure what placebo to use to control for a placebo. I think Star had better keep hoping that RJ Reynolds just gives up on fighting the nuisance lawsuits and decides to buy them off for a couple hundred million.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.
The article 1-Star Stocks Poised to Plunge: Star Scientific? originally appeared on Fool.com.
Fool contributorBrian Pacamparaowns no position in any of the companies mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Fool'sdisclosure policyalways gets a perfect score.